key: cord-0811063-ms71eu49
authors: Gribensk, Arthur; Schneider, Andrew; Gallaher, Jared R.; Reid, Trista S.; Kindell, Daniel G.; Charles, Anthony G.; Raff, Lauren A.
title: Post-hospitalization outcomes following extracorporeal membrane oxygenation (ECMO) for COVID-19
date: 2022-02-08
journal: Surgery
DOI: 10.1016/j.surg.2022.01.044
sha: 5c3381d9643bd01c48fc5b8ac7163862d10af315
doc_id: 811063
cord_uid: ms71eu49

BACKGROUND: Critical illness from COVID-19 is associated with prolonged hospitalization and high mortality rates. Extracorporeal membrane oxygenation (ECMO) is used for refractory severe acute respiratory distress syndrome (ARDS) in COVID-19 with outcomes comparable to other indications for ECMO. However, long-term functional outcomes have yet to be fully elucidated. METHODS: We performed a retrospective chart review of 24 consecutive patients who required ECMO due to COVID-19 associated severe ARDS and survived to hospital discharge. After hospitalization, we contacted patients and administered the Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 tool to assess longer-term outcomes. We abstracted demographics, clinical course, outcomes, and disposition variables from the electronic medical record. Descriptive statistical analysis was used on the retrospective data collection. RESULTS: Inpatient data were analyzed for 24 patients and 21/24 (88%) patients completed the PROMIS tool at an average of 8.8 months post-hospitalization. At hospital discharge, 62.5% of patients had ongoing oxygen requirements (nasal cannula, trach collar, or mechanical ventilation). 70.8% were discharged to a location other than home. However, at the time of follow-up, only 9.5% of patients required supplemental oxygen, all tracheostomies had been removed, and all patients resided at home. Patients reported relatively high levels of global physical function and though there was a high reported incidence of fatigue, overall pain scores were low. CONCLUSIONS: Long-term outcomes after ECMO for severe ARDS from COVID-19 are promising. ECMO therapy may confer morbidity benefits in COVID patients and remains a valuable modality with excellent functional outcomes and preserved quality of life for survivors.

In the ELSO COVID-19 cohort, among the survivors, there was a high incidence of discharge 66 to either an inpatient rehabilitation facility, long-term acute care hospital (LTACH), or another 67 inpatient hospital. This finding is attributable to critical illness deconditioning and the need for 

there is a lack of information regarding the long-term outcomes following ECMO for severe COVID-72 19 associated ARDS. 4, 8, 9 We hypothesized that there would be significant mental and physical 73 deficits noted by patients or their caregivers in the post-hospitalization period in patients after 74 COVID-19 associated ARDS requiring ECMO. We, therefore, analyzed survivors of severe ARDS from 75 COVID-19 that required veno-venous (VV) ECMO at our institution and performed a survey after 76 hospitalization to evaluate quality of life and functional status.

The University of North Carolina at Chapel Hill medical center is a 900-bed academic 79 tertiary care hospital. It is also a high-volume ECMO center, averaging around 60 cannulations per 80 year prior to COVID-19. Since early 2020, the ECMO volume has increased substantially and over 81 the past 19 months 152 patients with severe ARDS from COVID-19 have received ECMO. We 82 followed the standard, pre-COVID-19 ELSO guidelines for appropriate patient selection 10 , though 83 since this was a novel virus and much was unknown regarding best practices for this specific 84 patient population, we were more aggressive at cannulating patients if they were young or had a 85 short duration of intubation prior to progression to severe/refractory ARDS. More specifically, 86 patients were considered candidates for ECMO with the following criteria after ventilator 87 optimization: severe ARDS with severe hypoxia (PaO2:FiO2 < 100 for several hours; PaO2:FiO2 < 88 150 with concern for progressive/quick clinical decline); hypercarbia causing severe respiratory 89 acidosis (pH < 7.0) despite ventilator optimization; severe ARDS and/or severe hypercarbia and 

AIDS, active cancer) as contraindications. Currently, the overall survival rate to hospital discharge 97 after ECMO for COVID at our institution is 40%. For reference, the survival rate of all COVID-19 98 patients admitted to the ICU at our institution is 60%, though this includes a substantial number of 99 non-intubated and non-ARDS patients.

We performed a retrospective chart review to identify all patients who underwent VV 101 ECMO for COVID-19 from 4/01/2020 -4/10/2021. We included all patients that were successfully 102 decannulated from ECMO and were discharged or transferred from our hospital in the analysis (n = 103 24). During the study period 54 patients ultimately died while on ECMO or after decannulation but 104 prior to hospital discharge. Follow-up with post-ECMO survivors ranged from two months to a year 105 post decannulation, with a mean time of 8.8 months since hospital discharge. We excluded all 106 patients that died while on ECMO or expired before hospital discharge. We abstracted 107 demographics, clinical course, outcomes, and disposition variables from the electronic medical 108 record for each patient.

To assess functional status and quality of life, we utilized the Patient-Reported Outcomes 

The benefit of this survey is that each question has individual utility in assessing various aspects of 114 functional status in addition to a calculated total score (T-score) assessing global physical and 115 mental health. A lower T-score correlates with worse physical or mental health. The average T-116 score for the United States population is 50 points, with a range of 16.2-67.6. 11 We administered the 117 survey over the phone with each survivor from June -July 2021. The major benefit of this 118 questionnaire is that it is facile, decreasing the respondent burden and increasing the response rate.

The study personnel administered the survey to all eligible participants. Additionally, we queried 120 each participant about current supplemental oxygen usage, the presence of a tracheostomy, and the 121 use of tube feeds for nutrition.

Descriptive statistical analysis was used on the retrospective data collection. We report 

A total of 24 patients met the inclusion criteria for this study ( 

In this single-institution patient related outcomes study in a cohort of ECMO survivors 158 following COVID-19 associated ARDS, we show that overall average physical health T-scores were 159 only slightly lower than the national average (42.5 compared to 50, respectively), but mental health 160 scores were essentially the same (50.8 compared to 50, respectively). Though most patients did 161 report ongoing fatigue, they reported a relatively high level of physical function and minimal pain.

Furthermore, there was a very low incidence of ongoing supplemental oxygen requirement. All 

The T-scores between our study and this more heterogeneous cohort are similar even though all 193 patients in our study had severe ARDS that was refractory to conventional ventilatory management.

This is suggestive of a potential morbidity benefit to ECMO in the COVID-19 population, though 195 extensive further study is needed.

Similar to data reported by ELSO, we noted a high incidence of hospital discharge to another 197 facility, though 29.2% of our patients were discharged directly home with outpatient services. The 

COVID-19) Dashboard. 2021

Delta variant triggers new phase in the pandemic

Baseline 230 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted 231 to ICUs of the Lombardy Region

Extracorporeal membrane oxygenation support in COVID-19: an international 234 cohort study of the Extracorporeal Life Support Organization registry

Initial 237 ELSO Guidance Document: ECMO for COVID-19 Patients with Severe 238 Cardiopulmonary Failure

Full COVID-19 Registry Dashboard

Case 241 Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical 242

A Meta-analysis

Long-term health-related quality of life of adult patients treated with extracorporeal 245 membrane oxygenation (ECMO): An integrative review

Efficacy 248 and economic assessment of conventional ventilatory support versus 249